Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Drug Manufacturers — Specialty and Generic

Ironwood Pharmaceuticals, Inc. operates as a pharmaceutical company. The Company discovers, develops, manufactures, and commercializes marketed drugs. Ironwood products used in treatments of cholesterol, gastrointestinal, and cardiovascular diseases, as well as pain, inflammation, and others.
Website: ironwoodpharma.com


  • Bad financial results growth rate -36.8% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (-6.4%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield 25.3% (LTM)
  • Share price is 484.5% higher than minimum and 78.6% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (6.7x vs 7.9x)
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $20.5 mln (-4.375% of cap.)

Key Financials (Download financials)

Ticker: IRWD
Share price, USD:  (-2.6%)3.31
year average price 3.05  


year start price 0.61 2025-06-08

min close price 0.59 2025-06-09

max close price 5.39 2026-01-22

current price 3.31 2026-06-07
Common stocks: 153 837 992

Dividend Yield:  0.0%
FCF Yield LTM: 25.3%
EV / LTM EBITDA: 6.7x
EV / EBITDA annualized: 3.9x
Last revenue growth (y/y):  -47.3%
Last growth of EBITDA (y/y):  -26.3%
Historical revenue growth:  -10.0%
Historical growth of EBITDA:  -2.7%
EV / Sales: 3.7x
Margin (EBITDA LTM / Revenue): 55.1%

Target EV / EBITDA (hist percentile): 7.9x
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 509
Net Debt ($m): 581
EV (Enterprise Value): 1 090
EBITDA LTM (млн $): 163
EV / LTM EBITDA: 6.7x
Price to Book: -1.9x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-02-05zacks.com

Does Ironwood's Bullish 2026 View Signal Greater Linzess Adoption?

2026-01-02businesswire.com

Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance

2025-11-27zacks.com

IRWD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Pick?

2025-11-21zacks.com

Can Linzess Continue to Aid IRWD's Top Line After a Strong Q3?

2025-11-13zacks.com

IRWD Rises 110% in a Month: Should You Buy, Sell or Hold the Stock?

2025-11-10businesswire.com

Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance

2025-10-14zacks.com

Why Ironwood Pharmaceuticals (IRWD) is a Top Momentum Stock for the Long-Term

2025-08-08zacks.com

IRWD Stock Rises as Q2 Earnings & Revenues Trump Estimates

2025-08-07businesswire.com

Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance

2025-05-08zacks.com

IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol IRWD IRWD IRWD IRWD IRWD IRWD IRWD IRWD IRWD IRWD IRWD IRWD IRWD IRWD
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-10 2025-08-11 2024-11-07 2024-08-08 2024-05-09 2023-11-09 2023-08-09 2023-05-04 2022-11-03
acceptedDate 2025-11-10 07:01:07 2025-08-11 16:13:45 2025-03-31 07:07:37 2024-11-07 17:22:17 2024-08-08 16:06:09 2024-05-09 16:46:11 2024-02-16 07:01:34 2023-11-09 16:18:17 2023-08-09 16:02:57 2023-05-04 16:05:54 2023-02-16 17:21:07 2022-11-03 16:06:19 2022-02-17 17:46:19 2021-02-17 16:12:55
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 122M 85M 351M 92M 94M 75M 443M 114M 107M 104M 411M 109M 414M 390M
costOfRevenue 0 0 8M 0 506 000 513 000 6M 507 000 0 0 1M 0 70M 3M
grossProfit 122M 85M 344M 92M 94M 74M 437M 113M 107M 104M 409M 109M 343M 386M
grossProfitRatio 1 1 1 0.995 0.993 0.996 1 1 1
researchAndDevelopmentExpenses 22M 23M 111M 30M 30M 25M 116M 33M 1 125M 13M 44M 12M 70M 88M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 22M 17M 0 36M 37M 38M 0 36M 52M 31M 116M 29M 0 140M
otherExpenses 2M -250 000 139M 16 000 0 0 1 266M 0 0 0 -1M 0 41M 15M
operatingExpenses 47M 40M 251M 66M 67M 63M 1 382M 69M 1 178M 44M 159M 40M 111M 243M
costAndExpenses 47M 40M 258M 66M 67M 63M 1 388M 69M 1 178M 44M 160M 40M 181M 247M
interestIncome 930 000 818 000 4M 1M 1M 1M 19M 2M 9M 7M 10M 3M 726 000 2M
interestExpense 8M 8M 33M 9M 7M 7M 22M 10M 2M 2M 8M 1M 31M 29M
depreciationAndAmortization 475 000 467 000 2M 507 000 506 000 513 000 2M 507 000 22M 7M 1M 3M 2M 4M
ebitda 77M 47M 98M 27M 27M 12M 197M 46M -1 061M 67M 261M 71M 234M 142M
ebitdaratio 0.63 0.547 0.298 0.292 0.16 0.408 -9.884 0.647 0.656
operatingIncome 75M 45M 93M 26M 27M 11M -945M 40M -1 083M 60M 250M 68M 232M 143M
operatingIncomeRatio 0.618 0.532 0.28 0.286 0.153 0.352 -10.087 0.578 0.63
totalOtherIncomeExpensesNet -7M -7M -28M -8M -8M -6M -3M -5M -13M 6M 2M 1M -32M -34M
incomeBeforeTax 68M 38M 65M 17M 19M 5M -948M 32M -1 076M 66M 252M 70M 201M 109M
incomeBeforeTaxRatio 0.557 0.444 0.19 0.2 0.066 0.281 -10.022 0.633 0.643
incomeTaxExpense 28M 14M 64M 14M 20M 9M 83M 18M 13M 20M 77M 20M -328M 3M
netIncome 40M 24M 880 000 31M -860 000 -4M -1 002M 15M -1 062M 46M 175M 50M 528M 106M
netIncomeRatio 0.328 0.277 0.339 -0.009 -0.056 0.135 -9.892 0.439 0.463
eps 0.25 0.15 0.006 0.19 -0.005 -0.026 -6.45 0.098 -6.84 0.3 1.13 0.33 3.26 0.67
epsdiluted 0.23 0.14 0.19 -0.005 -0.026 0.082 -6.84 0.25 0.28
weightedAverageShsOut 162M 162M 159M 160M 159M 158M 155M 156M 155M 154M 154M 153M 162M 159M
weightedAverageShsOutDil 178M 162M 160M 160M 159M 158M 155M 187M 155M 187M 186M 184M 164M 161M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-31 2024-02-16 2023-02-16 2022-02-18 2021-02-17
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -29M -3M 2M -30M -28M
ebit 96M 196M 260M 232M 138M
nonOperatingIncomeExcludingInterest -3M -1 141M -10M 44 000 5M
netIncomeFromContinuingOperations 880 000 -1 032M 175M 528M 106M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 -4M 0 0
bottomLineNetIncome 880 000 -1 002M 180M 528M 106M
epsDiluted 0.006 -6.45 0.96 3.21 0.66

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol IRWD IRWD IRWD IRWD IRWD IRWD IRWD IRWD IRWD IRWD IRWD IRWD IRWD IRWD
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-10 2025-08-11 2024-11-07 2024-08-08 2024-05-09 2023-11-09 2023-08-09 2023-05-04 2022-11-03
acceptedDate 2025-11-10 07:01:07 2025-08-11 16:13:45 2025-03-31 07:07:37 2024-11-07 17:22:17 2024-08-08 16:06:09 2024-05-09 16:46:11 2024-02-16 07:01:34 2023-11-09 16:18:17 2023-08-09 16:02:57 2023-05-04 16:05:54 2023-02-16 17:21:07 2022-11-03 16:06:19 2022-02-17 17:46:19 2021-02-17 16:12:55
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 140M 93M 89M 88M 106M 122M 92M 110M 175M 740M 656M 574M 620M 364M
shortTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
cashAndShortTermInvestments 140M 93M 89M 88M 106M 122M 92M 110M 175M 740M 656M 574M 620M 364M
netReceivables 120M 86M 82M 76M 58M 72M 129M 125M 119M 116M 115M 117M 114M 122M
inventory 0 0 0 0 0 0 0 788 000 788 000 1M 1M 0 0 0
otherCurrentAssets 13M 13M 12M 14M 15M 15M 0 18M 23M 9M 0 8M 2M 9M
totalCurrentAssets 274M 192M 182M 179M 178M 208M 233M 254M 318M 866M 781M 699M 745M 496M
propertyPlantEquipmentNet 13M 14M 16M 16M 17M 17M 18M 19M 19M 20M 20M 21M 23M 26M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 2M 2M 3M 3M 3M 3M 4M 4M 4M 0 0 0 0 0
goodwillAndIntangibleAssets 2M 2M 3M 3M 3M 3M 4M 4M 4M 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0 510 000 0 0 15M 0 0 37M
taxAssets 102M 129M 144M 185M 193M 206M 212M 244M 258M 268M 284M 305M 0 0
otherNonCurrentAssets 5M 5M 6M 6M 4M 3M 4M 4M 4M 1M 847 000 16M 359M 943 000
totalNonCurrentAssets 122M 151M 169M 211M 217M 231M 238M 270M 286M 289M 320M 341M 382M 63M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 396M 343M 351M 390M 396M 439M 471M 524M 603M 1 155M 1 101M 1 040M 1 127M 559M
accountPayables 2M 1M 2M 3M 3M 6M 8M 5M 4M 118 000 483 000 795 000 935 000 661 000
shortTermDebt 203M 203M 0 3M 6M 203M 200M 202M 202M 3M 0 3M 117M 3M
taxPayables 0 764 000 521 000 986 000 935 000 2M 1M 1M 7M 0 656 000 0 0 0
deferredRevenue 1M 978 000 2M 0 935 000 2M 3M 59M 0 0 0 0 0 0
otherCurrentLiabilities 37M 27M 5M 42M 35M 41M 26M 14M 100M 21M 16M 23M 7M 15M
totalCurrentLiabilities 243M 233M 39M 49M 46M 252M 276M 281M 305M 24M 26M 27M 162M 32M
longTermDebt 395M 396M 584M 225M 637M 473M 498M 538M 614M 413M 396M 413M 337M 430M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 22M 22M 17M 427M 35M 43M 28M 31M 31M 12M 10M 418M 4M 14M
totalNonCurrentLiabilities 418M 419M 613M 651M 672M 517M 541M 569M 645M 425M 423M 422M 359M 464M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 14M 14M 15M 16M 17M 14M 18M 18M 19M 19M 20M 20M 22M 20M
totalLiabilities 660M 651M 652M 701M 717M 769M 817M 850M 950M 448M 448M 449M 521M 497M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 163 000 162 000 160 000 160 000 160 000 159 000 156 000 156 000 156 000 155 000 154 000 153 000 162 000 161 000
retainedEarnings -1 671M -1 712M -1 698M -1 700M -1 704M -1 703M -1 699M -1 698M -1 713M -651M -696M -745M -938M -1 466M
accumulatedOtherComprehensiveIncomeLoss -2M -2M 923 000 -2M -470 000 -922 000 -3M -752 000 0 0 0 0 -0 0
othertotalStockholdersEquity 1 409M 1 405M 1 391M 1 382M 1 373M 1 372M 1 366M 1 357M 1 336M
totalStockholdersEquity -264M -308M -301M -311M -322M -331M -346M -326M -347M 707M 652M 591M 606M 63M
totalEquity -264M -308M -301M -311M -322M -331M -346M -328M -348M 707M 652M 591M 606M 63M
totalLiabilitiesAndStockholdersEquity 396M 343M 390M 396M 439M 524M 603M 1 155M 1 040M
minorityInterest 0 0 0 0 0 0 0 -2M -1M 0 0 0 0 0
totalLiabilitiesAndTotalEquity 396M 343M 351M 390M 396M 439M 471M 524M 603M 1 155M 1 101M 1 040M 1 127M 559M
totalInvestments 0 0 0 0 0 0 0 510 000 0 0 15M 0 0 37M
totalDebt 598M 599M 599M 215M 640M 690M 716M 741M 816M 416M 416M 416M 476M 454M
netDebt 458M 506M 511M 127M 535M 569M 623M 630M 640M -325M -240M -158M -144M 89M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-31 2024-02-16 2023-02-16 2022-02-18 2021-02-17
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 82M 129M 115M 114M 122M
otherReceivables 0 0 0 0 0
prepaids 0 12M 8M 9M 0
totalPayables 3M 9M 1M 935 000 661 000
otherPayables 521 000 1M 656 000 0 0
accruedExpenses 26M 36M 5M 33M 13M
capitalLeaseObligationsCurrent 3M 3M 3M 3M 0
capitalLeaseObligationsNonCurrent 12M 15M 17M 18M 20M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 1 395M 1 355M 1 349M 1 543M 1 529M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol IRWD IRWD IRWD IRWD IRWD IRWD IRWD IRWD IRWD IRWD IRWD IRWD IRWD IRWD
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-10 2025-08-11 2024-11-07 2024-08-08 2024-05-09 2023-11-09 2023-08-09 2023-05-04 2022-11-03
acceptedDate 2025-11-10 07:01:07 2025-08-11 16:13:45 2025-03-31 07:07:37 2024-11-07 17:22:17 2024-08-08 16:06:09 2024-05-09 16:46:11 2024-02-16 07:01:34 2023-11-09 16:18:17 2023-08-09 16:02:57 2023-05-04 16:05:54 2023-02-16 17:21:07 2022-11-03 16:06:19 2022-02-17 17:46:19 2021-02-17 16:12:55
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 40M 24M 880 000 4M -860 000 -4M -1 002M 14M -1 089M 46M 175M 50M 528M 106M
depreciationAndAmortization 475 000 467 000 2M 507 000 506 000 513 000 2M 507 000 270 000 286 000 1M 363 000 2M 4M
deferredIncomeTax 28M 14M 68M 8M 13M 6M 73M 14M 10M 17M 66M 16M -333M 7M
stockBasedCompensation 4M 5M 30M 8M 9M 8M 32M 8M 8M 7M 27M 7M 22M 31M
changeInWorkingCapital -25M -59M 739 000 -11M 11M 34M 11M -5M 15M 10M 3M -5M 18M -941 000
accountsReceivables -34M -46M 47M 0 14M 57M 924 000 -6M -3M 14M 8M -14M 8M 4M
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0 648 000
accountsPayables 11M -14M -20M 0 -2M -13M 12M 7M 18M 705 000 -8M 5M -3M -8M
otherWorkingCapital -2M 2M -26M -11M -502 000 -11M -2M -6M 578 000 -15M 3M 5M 13M 2M
otherNonCashItems 851 000 919 000 2M 355 000 -2M -35M 1 068M 586 000 1 091M 383 000 2M 249 000 25M 22M
netCashProvidedByOperatingActivities 48M -15M 104M 10M 33M 45M 183M 32M 35M 80M 274M 69M 262M 169M
investmentsInPropertyPlantAndEquipment -2000 -2000 -142 000 0 -58 000 -68 000 -273 000 -49 000 0 -13 000 -136 000 -66 000 -265 000 -2M
acquisitionsNet 0 0 0 0 0 0 -1 026M -23M 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherInvestingActivites 0 0 -16 000 -58 000 0 -23M -999M 0 0
netCashUsedForInvestingActivites -2000 -2000 -16 000 -58 000 -68 000 -23M -999M -13 000 -66 000
debtRepayment 0 0 -25M -50M -25M -75M 0 0 0
commonStockIssued 0 88 000 0 0 10M 12 000 0 4M 0
commonStockRepurchased 0 0 0 0 0 -616 000 0 0 0 0 -126M 0 -24M 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 0 -2M -121 000 -616 000 -75M 399M 0 797 000
netCashUsedProvidedByFinancingActivities 0 88 000 -27M -49M -16M -75M 399M 4M 797 000
effectOfForexChangesOnCash -26 000 -647 000 -32 000 -26 000 -51 000 24 000 -53 000 -3000 -35M 0 0 0 0 0
netChangeInCash 48M -16M -4M -17M -16M 29M -566M -65M -565M 84M 36M 70M 257M 186M
cashAtEndOfPeriod 140M 93M 89M 88M 106M 122M 92M 111M 177M 742M 658M 576M 622M 365M
cashAtBeginningOfPeriod 93M 108M 92M 106M 122M 92M 658M 177M 742M 658M 622M 506M 365M 179M
operatingCashFlow 48M -15M 104M 10M 33M 45M 183M 32M 35M 80M 274M 69M 262M 169M
capitalExpenditure -2000 -2000 -142 000 0 -58 000 -68 000 -273 000 -49 000 0 -13 000 -136 000 -66 000 -265 000 -2M
freeCashFlow 48M -15M 103M 10M 33M 45M 183M 32M 35M 80M 274M 69M 262M 167M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-31 2024-02-16 2023-02-16 2022-02-18 2021-02-17
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 0 0 0
netCashProvidedByInvestingActivities -142 000 -1 026M -136 000 -265 000 -2M
netDebtIssuance -115M 300M -121M 0 0
longTermNetDebtIssuance -115M 300M -121M 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 11M 6M -126M -24M 19M
netCommonStockIssuance 11M 6M -126M -24M 19M
commonStockIssuance 11M 6M 0 0 19M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -3M -29M 10M 20M 0
netCashProvidedByFinancingActivities -107M 277M -238M -5M 19M
incomeTaxesPaid 8M 10M 5M 3M 2M
interestPaid 33M 14M 6M 7M 7M

Earning call transcript

2024 q4
2025-02-27 ET (fiscal 2024 q4)
2024 q3
2024-11-07 ET (fiscal 2024 q3)
2024 q2
2024-08-09 ET (fiscal 2024 q2)
2024 q1
2024-05-09 ET (fiscal 2024 q1)
2023 q4
2024-02-15 ET (fiscal 2023 q4)
2023 q3
2023-11-09 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-06 ET (fiscal 2023 q1)
2022 q4
2023-02-16 ET (fiscal 2022 q4)
2022 q3
2022-11-03 ET (fiscal 2022 q3)
2022 q2
2022-08-06 ET (fiscal 2022 q2)
2022 q1
2022-05-08 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-05-07 11:05 ET
Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance
2026-05-04 11:05 ET
Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)
2026-04-30 20:05 ET
Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call
2026-04-23 11:05 ET
Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026
2026-03-04 ET
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
2026-02-25 ET
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook
2026-02-18 21:21 ET
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call
2026-01-02 ET
Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance
2025-11-10 12:05 ET
Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance
2025-08-07 ET
Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance
2025-05-07 ET
Ironwood Pharmaceuticals Reports First Quarter 2025 Results
2025-04-30 ET
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
2025-04-25 ET
Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance
2025-04-22 ET
Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support
2025-04-14 ET
Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide
2025-03-27 ET
Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing
2025-02-27 ET
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance
2025-02-20 ET
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call
2025-01-29 ET
Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future
2024-11-26 ET
Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference
2024-11-13 ET
Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
2024-11-07 12:00 ET
Ironwood Pharmaceuticals Reports Third Quarter 2024 Results
2024-10-28 11:00 ET
Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024
2024-10-24 20:00 ET
Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call
2024-08-29 20:01 ET
Ironwood Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
2024-08-08 11:00 ET
Ironwood Pharmaceuticals Reports Second Quarter 2024 Results
2024-07-25 20:00 ET
Ironwood Pharmaceuticals to Host Second Quarter 2024 Investor Update Call
2024-05-30 20:01 ET
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
2024-05-21 10:00 ET
Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
2024-05-09 11:00 ET
Ironwood Pharmaceuticals Reports First Quarter 2024 Results
2024-05-06 20:01 ET
Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference
2024-05-02 18:33 ET
Stonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus Management
2024-05-01 11:30 ET
Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024
2024-04-25 20:01 ET
Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call
2024-03-28 11:30 ET
Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)
2024-02-29 11:00 ET
Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
2024-02-23 12:30 ET
Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference
2024-02-15 12:00 ET
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance
2024-02-01 21:01 ET
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call
2024-01-09 00:00 ET
Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation
2024-01-08 11:00 ET
Ironwood Pharmaceuticals Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance
2024-01-03 21:01 ET
Ironwood Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-12 21:01 ET
Ironwood Announces the Completion of Squeeze-Out Merger With VectivBio
2023-11-30 14:45 ET
Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management
2023-11-21 21:01 ET
Ironwood Pharmaceuticals to Participate in the Piper Sandler 35th Annual Healthcare Conference
2023-11-09 12:00 ET
Ironwood Pharmaceuticals Reports Third Quarter 2023 Results
2023-10-26 20:01 ET
Ironwood Pharmaceuticals to Host Third Quarter 2023 Investor Update Call
2023-10-23 11:30 ET
Ironwood Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific Meeting
2023-10-16 10:00 ET
Ironwood Pharmaceuticals Presents Positive Final Data from STARS Nutrition, a Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity (CIC) at United European Gastroenterology Week
2023-10-05 11:30 ET
Ironwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
2023-08-08 11:00 ET
Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance
2023-07-25 20:01 ET
Ironwood Pharmaceuticals to Host Second Quarter 2023 Investor Update Call
2023-06-29 12:30 ET
Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares
2023-06-16 11:00 ET
Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio
2023-06-12 20:05 ET
Ironwood Pharmaceuticals Announces FDA Approval of New Indication for LINZESS® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients Ages 6-17 Years-Old
2023-05-22 10:57 ET
Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases
2023-05-09 20:01 ET
Ironwood Pharmaceuticals to Participate in The JMP Securities Life Sciences Conference
2023-05-08 11:30 ET
Ironwood Presents New Data on Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old at Digestive Disease Week® 2023
2023-05-04 11:00 ET
Ironwood Pharmaceuticals Reports First Quarter 2023 Results; Maintains Full Year 2023 Financial Guidance
2023-04-24 11:30 ET
Ironwood to Present New Data at Digestive Disease Week® 2023 Demonstrating Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
2023-04-20 20:01 ET
Ironwood Pharmaceuticals to Host First Quarter 2023 Investor Update Call
2023-02-27 21:01 ET
Ironwood Pharmaceuticals to Participate in Upcoming Investor Conferences
2023-02-16 12:00 ET
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results
2023-02-13 12:30 ET
Ironwood Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of Supplemental New Drug Application for LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
2023-02-02 21:01 ET
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Investor Update Call
2023-01-09 11:00 ET
Ironwood Pharmaceuticals Provides Update on FY 2022 Financial Guidance and Announces FY 2023 Financial Guidance
2023-01-04 21:01 ET
Ironwood Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-11-22 21:01 ET
Ironwood Pharmaceuticals to Participate in the Piper Sandler 34th Annual Healthcare Conference
2022-11-03 11:01 ET
Ironwood Pharmaceuticals Reports Strong Third Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance
2022-10-20 20:01 ET
Ironwood Pharmaceuticals to Host Third Quarter 2022 Investor Update Call
2022-09-06 11:00 ET
Ironwood Pharmaceuticals Reports Positive Topline Data from Phase III Trial of LINZESS® (linaclotide) in Pediatric Patients Aged 6-17 with Functional Constipation
2022-09-01 20:01 ET
Ironwood Pharmaceuticals to Present at the 2022 Wells Fargo Healthcare Conference
2022-08-04 11:00 ET
Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS® Prescription Demand
2022-07-21 20:01 ET
Ironwood Pharmaceuticals to Host Second Quarter 2022 Investor Update Call
2022-05-25 11:30 ET
Ironwood Presents New Data Demonstrating Potential of IW-3300 for Visceral Pain at Digestive Disease Week® (DDW) 2022
2022-05-09 12:00 ET
Ironwood Pharmaceuticals to Present New IW-3300 and Linaclotide Data at Digestive Disease Week® 2022
2022-05-05 11:00 ET
Ironwood Pharmaceuticals Reports First Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance
2022-04-21 20:01 ET
Ironwood Pharmaceuticals to Host First Quarter 2022 Investor Update Call
2022-03-02 12:30 ET
Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences
2022-02-17 12:00 ET
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; LINZESS® (linaclotide) Achieves Blockbuster Status as U.S. Net Sales Exceed $1 Billion in 2021
2022-02-03 12:30 ET
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Investor Update Call
2022-01-10 12:20 ET
Ironwood Pharmaceuticals Provides Update on FY 2021 Financial Guidance and Announces FY 2022 Financial Guidance
2022-01-05 12:30 ET
Ironwood Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
2021-12-01 12:30 ET
Ironwood Pharmaceuticals Appoints Sravan K. Emany as Chief Financial Officer
2021-11-04 11:15 ET
Ironwood Pharmaceuticals Reports Third Quarter 2021 Results and Provides Corporate Development Update
2021-11-04 11:00 ET
Ironwood Pharmaceuticals Expands Pipeline by Signing an Option Agreement to Acquire an Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC) in the U.S.
2021-10-25 11:30 ET
More than 90% of Surveyed IBS-C Patients Who Had an ER Visit or Hospitalization in the Past Year Identified Abdominal Pain as a Symptom That Led to the Visit, According to Data Announced by Ironwood Pharmaceuticals at ACG 2021
2021-10-21 11:00 ET
Ironwood Pharmaceuticals to Host Third Quarter 2021 Investor Update Call
2021-09-02 11:30 ET
Ironwood Pharmaceuticals to Participate in Upcoming September Investor Conferences
2021-08-26 11:00 ET
Ironwood Pharmaceuticals Announces FDA Approval of Revised LINZESS® (linaclotide) Label
2021-08-05 11:00 ET
Ironwood Pharmaceuticals Reports Strong Second-Quarter 2021 Results, Raises Full-Year Guidance
2021-08-03 11:30 ET
Ironwood Pharmaceuticals Appoints John Minardo as Chief Legal Officer
2021-07-22 20:01 ET
Ironwood Pharmaceuticals to Host Second Quarter 2021 Investor Update Call
2021-06-16 11:45 ET
Ironwood Pharmaceuticals Announces That The American Journal of Gastroenterology Publishes Full Results from Positive LINZESS® (linaclotide) Phase IIIb Trial in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)
2021-06-07 20:01 ET
Ironwood Pharmaceuticals Announces Leadership Updates
2021-05-26 20:01 ET
Ironwood Pharmaceuticals Announces Agreement with Teva Involving LINZESS® (linaclotide) 72 mcg Dosage Strength
2021-05-24 12:00 ET
More Than a Third of Surveyed IBS-C Patients Reported That Their Symptoms Worsened During COVID-19 According to New Survey Findings Presented by Ironwood Pharmaceuticals at Digestive Disease Week® (DDW)
2021-05-17 12:30 ET
Ironwood Pharmaceuticals to Present New Linaclotide Data and Unveil Findings From GI Disease Surveys at Digestive Disease Week® 2021
2021-05-06 11:03 ET
Ironwood Pharmaceuticals Announces New $150 Million Share Repurchase Program
2021-05-06 11:00 ET
Ironwood Pharmaceuticals Reports First Quarter 2021 Results
2021-04-22 20:01 ET
Ironwood Pharmaceuticals to Host First Quarter 2021 Investor Update Call
2021-02-19 21:01 ET
Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences
2021-02-17 12:01 ET
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year 2021 Financial Guidance
2021-02-08 21:01 ET
Ironwood Pharmaceuticals Announces CEO Transition
2021-02-03 21:01 ET
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2020 Investor Update Call
2021-01-05 12:30 ET
Ironwood Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
2020-12-03 13:30 ET
Ironwood Pharmaceuticals Appoints Jay P. Shepard to Board of Directors
2020-11-06 21:01 ET
Ironwood Pharmaceuticals to Present at the 29th Annual Credit Suisse Healthcare Conference
2020-11-05 21:03 ET
Ironwood Pharmaceuticals Reports Strong Third Quarter 2020 Results and Increases Full Year 2020 Financial Guidance
2020-11-05 21:01 ET
Ironwood Pharmaceuticals Appoints Alexander Denner, Ph.D., to Board of Directors
2020-10-22 20:01 ET
Ironwood Pharmaceuticals to Host Third Quarter 2020 Investor Update Call
2020-09-29 11:15 ET
Ironwood to Discontinue IW-3718 Development Program Following Results from Planned Efficacy Assessment
2020-09-02 20:00 ET
Ironwood Pharmaceuticals to Participate in Upcoming September Investor Conferences
2020-08-06 11:00 ET
Ironwood Pharmaceuticals Reports Second Quarter 2020 Results; Delivered GAAP Net Income of $25 Million and Adjusted EBITDA of $33 Million
2020-07-23 20:05 ET
Ironwood Pharmaceuticals to Host Second Quarter 2020 Investor Update Call
2020-07-21 11:00 ET
Ironwood Announces Updates Designed to Strengthen IW-3718 Phase III Program for Refractory Gastroesophageal Reflux Disease (GERD)
2020-05-27 12:00 ET
Ironwood and AbbVie Report Top-line Phase II Data for MD-7246 in Patients with Abdominal Pain Associated with Irritable Bowel Syndrome with Diarrhea (IBS-D)
2020-05-06 20:05 ET
Ironwood Pharmaceuticals Reports First Quarter 2020 Results and Provides Update on Impact of COVID-19 Pandemic
2020-04-28 20:05 ET
Ironwood and Allergan Receive Notices of Allowance for Patent Applications Covering 72 mcg Dose of LINZESS® (linaclotide)
2020-04-16 20:05 ET
Ironwood Pharmaceuticals to Host First Quarter 2020 Investor Update Call
2020-03-26 13:00 ET
Ironwood Pharmaceuticals Provides Update on Impact of COVID-19
2020-02-26 21:05 ET
Ironwood Pharmaceuticals Announces Publication of Positive IW-3718 Phase IIb Data in Gastroenterology
2020-02-25 21:05 ET
Ironwood Pharmaceuticals to Present at Upcoming March Investor Conferences
2020-02-19 21:05 ET
Ironwood Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference
2020-02-13 12:00 ET
Ironwood Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2019 Results, Exceeding Full Year 2019 Guidance; Provides Full Year 2020 Guidance
2020-01-30 21:05 ET
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2019 Investor Update Call
2020-01-22 14:20 ET
Ironwood and Allergan Announce Settlement with Teva Resolving LINZESS® (linaclotide) Patent Litigation
2020-01-06 13:00 ET
Ironwood and Allergan Announce Settlement Resolving LINZESS® (linaclotide) Patent Litigation
2020-01-02 21:01 ET
Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
2019-11-05 21:05 ET
Ironwood Pharmaceuticals to Present at the 28th Annual Credit Suisse Healthcare Conference
2019-10-31 11:00 ET
Ironwood Pharmaceuticals Reports Third Quarter 2019 Results; Raises Full Year 2019 Guidance
2019-10-28 12:00 ET
Ironwood Pharmaceuticals to Highlight New Data at the American College of Gastroenterology 2019 Annual Scientific Meeting
2019-10-17 20:05 ET
Ironwood Pharmaceuticals to Host Third Quarter 2019 Investor Update Call
2019-09-18 06:00 ET
Ironwood Pharmaceuticals and AstraZeneca Amend LINZESS® (linaclotide) Collaboration in China
2019-04-16 20:02 ET
Ironwood Pharmaceuticals Announces Adjustment of Conversion Rate for its 2.25% Convertible Senior Notes due 2020
2019-04-01 20:02 ET
Ironwood Pharmaceuticals Completes Separation of Cyclerion Therapeutics and Becomes a Gastrointestinal (GI)-focused Healthcare Company
2019-03-14 20:54 ET
Ironwood Announces Effectiveness of Cyclerion Form 10 Registration Statement

SEC forms

Show financial reports only

SEC form 10
2026-05-07 20:08 ET
Ironwood Pharmaceuticals published news for 2026 q1
SEC form 8
2026-05-07 11:10 ET
Ironwood Pharmaceuticals published news for 2026 q1
SEC form 8
2026-05-07 11:10 ET
Ironwood Pharmaceuticals published news for 2026 q1
SEC form 8
2026-02-25 07:11 ET
Ironwood Pharmaceuticals published news for 2025 q4
SEC form 8
2026-02-25 07:11 ET
Ironwood Pharmaceuticals reported for 2025 q4
SEC form 8
2025-11-10 07:12 ET
Ironwood Pharmaceuticals published news for 2025 q3
SEC form 8
2025-11-10 07:12 ET
Ironwood Pharmaceuticals published news for 2025 q3
SEC form 10
2025-11-10 07:01 ET
Ironwood Pharmaceuticals reported for 2025 q3
SEC form 10
2025-08-11 20:13 ET
Ironwood Pharmaceuticals published news for 2025 q2
SEC form 8
2025-08-07 11:11 ET
Ironwood Pharmaceuticals published news for 2025 q2
SEC form 8
2025-08-07 11:11 ET
Ironwood Pharmaceuticals reported for 2025 q2
SEC form 8
2025-07-10 20:06 ET
Ironwood Pharmaceuticals published news for 2025 q2
SEC form 8
2025-07-10 20:06 ET
Ironwood Pharmaceuticals published news for 2025 q2
SEC form 10
2025-05-12 20:36 ET
Ironwood Pharmaceuticals published news for 2025 q1
SEC form 10
2025-05-12 00:00 ET
Ironwood Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-07 11:11 ET
Ironwood Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-07 11:11 ET
Ironwood Pharmaceuticals reported for 2025 q1
SEC form 8
2025-04-25 00:00 ET
Ironwood Pharmaceuticals published news for 2025 q1
SEC form 8
2025-04-25 00:00 ET
Ironwood Pharmaceuticals published news for 2025 q1
SEC form 8
2025-04-14 11:07 ET
Ironwood Pharmaceuticals published news for 2025 q1
SEC form 8
2025-04-14 11:07 ET
Ironwood Pharmaceuticals published news for 2025 q1
SEC form 10
2025-03-31 11:07 ET
Ironwood Pharmaceuticals published news for 2024 q4
SEC form 10
2025-03-31 00:00 ET
Ironwood Pharmaceuticals published news for 2024 q4
SEC form 8
2025-02-27 07:08 ET
Ironwood Pharmaceuticals published news for 2024 q4
SEC form 8
2025-02-27 07:08 ET
Ironwood Pharmaceuticals reported for 2024 q4
SEC form 10
2024-11-07 17:22 ET
Ironwood Pharmaceuticals reported for 2024 q3
SEC form 8
2024-11-07 07:07 ET
Ironwood Pharmaceuticals published news for 2024 q3
SEC form 8
2024-11-07 07:07 ET
Ironwood Pharmaceuticals published news for 2024 q3
SEC form 10
2024-08-08 16:06 ET
Ironwood Pharmaceuticals published news for 2024 q2
SEC form 8
2024-08-08 07:07 ET
Ironwood Pharmaceuticals published news for 2024 q2
SEC form 8
2024-08-08 07:07 ET
Ironwood Pharmaceuticals reported for 2024 q2
SEC form 10
2024-08-08 00:00 ET
Ironwood Pharmaceuticals published news for 2024 q2
SEC form 10
2024-05-09 00:00 ET
Ironwood Pharmaceuticals reported for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Ironwood Pharmaceuticals published news for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Ironwood Pharmaceuticals published news for 2024 q1
SEC form 10
2024-02-16 00:00 ET
Ironwood Pharmaceuticals reported for 2023 q4
SEC form 8
2024-02-15 00:00 ET
Ironwood Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-15 00:00 ET
Ironwood Pharmaceuticals published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Ironwood Pharmaceuticals published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Ironwood Pharmaceuticals published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Ironwood Pharmaceuticals published news for 2023 q4
SEC form 10
2023-11-09 16:18 ET
Ironwood Pharmaceuticals published news for 2023 q3
SEC form 8
2023-11-09 07:07 ET
Ironwood Pharmaceuticals reported for 2023 q3
SEC form 10
2023-11-09 00:00 ET
Ironwood Pharmaceuticals published news for 2023 q3
SEC form 10
2023-08-09 16:02 ET
Ironwood Pharmaceuticals published news for 2023 q2
SEC form 10
2023-08-09 00:00 ET
Ironwood Pharmaceuticals published news for 2023 q2
SEC form 6
2023-08-08 07:08 ET
Ironwood Pharmaceuticals reported for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Ironwood Pharmaceuticals published news for 2023 q2
SEC form 6
2023-06-30 16:05 ET
Ironwood Pharmaceuticals published news for 2023 q1
SEC form 6
2023-06-22 16:08 ET
Ironwood Pharmaceuticals published news for 2023 q1
SEC form 10
2023-05-04 00:00 ET
Ironwood Pharmaceuticals published news for 2023 q1
SEC form 8
2023-05-04 00:00 ET
Ironwood Pharmaceuticals reported for 2023 q1
SEC form 6
2023-04-11 08:30 ET
Ironwood Pharmaceuticals published news for 2023 q1
SEC form 10
2023-02-16 17:21 ET
Ironwood Pharmaceuticals reported for 2022 q4
SEC form 6
2023-02-16 07:09 ET
Ironwood Pharmaceuticals published news for 2022 q4
SEC form 10
2023-02-16 00:00 ET
Ironwood Pharmaceuticals reported for 2022 q4
SEC form 8
2023-02-16 00:00 ET
Ironwood Pharmaceuticals reported for 2022 q4
SEC form 6
2023-01-09 06:30 ET
Ironwood Pharmaceuticals published news for 2022 q4
SEC form 8
2023-01-09 00:00 ET
Ironwood Pharmaceuticals published news for 2022 q4
SEC form 6
2022-12-19 16:14 ET
Ironwood Pharmaceuticals published news for 2022 q3
SEC form 10
2022-11-03 16:06 ET
Ironwood Pharmaceuticals reported for 2022 q3
SEC form 6
2022-11-03 07:00 ET
Ironwood Pharmaceuticals published news for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Ironwood Pharmaceuticals reported for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Ironwood Pharmaceuticals reported for 2022 q3
SEC form 10
2022-08-04 16:11 ET
Ironwood Pharmaceuticals reported for 2022 q2
SEC form 6
2022-08-04 07:06 ET
Ironwood Pharmaceuticals published news for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Ironwood Pharmaceuticals reported for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Ironwood Pharmaceuticals reported for 2022 q2
SEC form 6
2022-06-08 16:05 ET
Ironwood Pharmaceuticals published news for 2022 q1
SEC form 6
2022-06-03 16:06 ET
Ironwood Pharmaceuticals published news for 2022 q1
SEC form 6
2022-06-03 16:06 ET
Ironwood Pharmaceuticals published news for 2022 q1
SEC form 6
2022-06-03 16:06 ET
Ironwood Pharmaceuticals published news for 2022 q1
SEC form 6
2022-06-03 16:05 ET
Ironwood Pharmaceuticals published news for 2022 q1
SEC form 6
2022-06-03 16:05 ET
Ironwood Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-05 16:07 ET
Ironwood Pharmaceuticals reported for 2022 q1
SEC form 6
2022-05-05 07:07 ET
Ironwood Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-05 00:00 ET
Ironwood Pharmaceuticals reported for 2022 q1
SEC form 8
2022-05-05 00:00 ET
Ironwood Pharmaceuticals reported for 2022 q1
SEC form 6
2022-04-21 16:12 ET
Ironwood Pharmaceuticals published news for 2022 q1
SEC form 10
2022-02-18 00:00 ET
Ironwood Pharmaceuticals published news for 2021 q4
SEC form 10
2022-02-17 17:46 ET
Ironwood Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-17 07:06 ET
Ironwood Pharmaceuticals published news for 2021 q4
SEC form 8
2022-02-17 00:00 ET
Ironwood Pharmaceuticals published news for 2021 q4
SEC form 6
2022-01-10 07:33 ET
Ironwood Pharmaceuticals published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
Ironwood Pharmaceuticals published news for 2021 q4
SEC form 6
2021-12-01 07:37 ET
Ironwood Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-04 16:07 ET
Ironwood Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-04 07:19 ET
Ironwood Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-04 00:00 ET
Ironwood Pharmaceuticals published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
Ironwood Pharmaceuticals published news for 2021 q3
SEC form 10
2021-08-05 16:08 ET
Ironwood Pharmaceuticals published news for 2021 q2
SEC form 6
2021-08-05 07:05 ET
Ironwood Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Ironwood Pharmaceuticals published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Ironwood Pharmaceuticals published news for 2021 q2
SEC form 6
2021-07-22 16:07 ET
Ironwood Pharmaceuticals published news for 2021 q2
SEC form 6
2021-06-24 17:16 ET
Ironwood Pharmaceuticals published news for 2021 q1
SEC form 6
2021-06-07 16:06 ET
Ironwood Pharmaceuticals published news for 2021 q1
SEC form 6
2021-06-03 17:10 ET
Ironwood Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-06 16:10 ET
Ironwood Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-06 07:07 ET
Ironwood Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Ironwood Pharmaceuticals published news for 2021 q1
SEC form 8
2021-05-06 00:00 ET
Ironwood Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-22 16:12 ET
Ironwood Pharmaceuticals published news for 2021 q1
SEC form 6
2021-03-30 16:43 ET
Ironwood Pharmaceuticals published news for 2020 q4
SEC form 6
2021-03-15 16:53 ET
Ironwood Pharmaceuticals published news for 2020 q4
SEC form 10
2021-02-17 16:12 ET
Ironwood Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-17 07:07 ET
Ironwood Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-08 16:09 ET
Ironwood Pharmaceuticals published news for 2020 q4
SEC form 6
2021-01-11 07:34 ET
Ironwood Pharmaceuticals published news for 2020 q4
SEC form 6
2020-12-16 16:00 ET
Ironwood Pharmaceuticals published news for 2020 q3
SEC form 6
2020-12-03 08:36 ET
Ironwood Pharmaceuticals published news for 2020 q3
SEC form 10
2020-11-05 16:49 ET
Ironwood Pharmaceuticals published news for 2020 q3
SEC form 6
2020-11-05 16:11 ET
Ironwood Pharmaceuticals published news for 2020 q3